Edwards Lifesciences Corp. ((EW)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Edwards Lifesciences Corp. is conducting the 2019-06 TRISCEND Study to evaluate the safety and clinical efficacy of the Edwards EVOQUE Tricuspid Valve Replacement System. This prospective, multi-center study aims to assess the device’s performance in replacing the tricuspid valve through a transcatheter approach, which could significantly impact patient outcomes with tricuspid valve disease.
The study tests the Edwards EVOQUE Tricuspid Valve Replacement, a transcatheter device designed to replace the tricuspid valve, offering a less invasive treatment option for patients with tricuspid valve disease.
This interventional study uses a single-group assignment model without masking, focusing on treatment as the primary purpose. It aims to provide clear insights into the device’s effectiveness and safety.
The study began on May 6, 2020, with primary completion expected by December 16, 2024, and the estimated study completion by August 13, 2025. These dates are crucial for tracking the study’s progress and anticipating when results might impact the market.
The outcome of this study could influence Edwards Lifesciences’ stock performance, as successful results may enhance investor confidence and competitive positioning in the medical device industry. The ongoing study reflects Edwards Lifesciences’ commitment to innovation in heart valve replacement technologies.
The study is ongoing, with further details available on the ClinicalTrials portal.